CA2960916C - Spirocyclic inhibitors of cathepsin c - Google Patents

Spirocyclic inhibitors of cathepsin c Download PDF

Info

Publication number
CA2960916C
CA2960916C CA2960916A CA2960916A CA2960916C CA 2960916 C CA2960916 C CA 2960916C CA 2960916 A CA2960916 A CA 2960916A CA 2960916 A CA2960916 A CA 2960916A CA 2960916 C CA2960916 C CA 2960916C
Authority
CA
Canada
Prior art keywords
compound
mmol
group
formula
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2960916A
Other languages
English (en)
French (fr)
Other versions
CA2960916A1 (en
Inventor
Viktor VINTONYAK
Matthias Grauert
Marc Grundl
Alexander Pautsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CA2960916A1 publication Critical patent/CA2960916A1/en
Application granted granted Critical
Publication of CA2960916C publication Critical patent/CA2960916C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2960916A 2014-09-12 2015-09-08 Spirocyclic inhibitors of cathepsin c Active CA2960916C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14184613 2014-09-12
EP14184613.9 2014-09-12
PCT/EP2015/070449 WO2016038007A1 (en) 2014-09-12 2015-09-08 Spirocyclic inhibitors of cathepsin c

Publications (2)

Publication Number Publication Date
CA2960916A1 CA2960916A1 (en) 2016-03-17
CA2960916C true CA2960916C (en) 2023-03-07

Family

ID=51535355

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2960916A Active CA2960916C (en) 2014-09-12 2015-09-08 Spirocyclic inhibitors of cathepsin c

Country Status (34)

Country Link
US (3) US9540373B2 (show.php)
EP (2) EP3191487B1 (show.php)
JP (2) JP2017526716A (show.php)
KR (1) KR102510588B1 (show.php)
CN (2) CN108047240B (show.php)
AP (1) AP2017009733A0 (show.php)
AU (1) AU2015314355B2 (show.php)
BR (1) BR112017003433B1 (show.php)
CA (1) CA2960916C (show.php)
CL (1) CL2017000432A1 (show.php)
CO (1) CO2017002268A2 (show.php)
CY (1) CY1123033T1 (show.php)
DK (1) DK3191487T3 (show.php)
EA (1) EA031376B1 (show.php)
ES (1) ES2749009T3 (show.php)
HK (1) HK1255362A1 (show.php)
HR (1) HRP20191756T1 (show.php)
HU (1) HUE047208T2 (show.php)
IL (1) IL250262B (show.php)
LT (1) LT3191487T (show.php)
MX (2) MX367316B (show.php)
MY (1) MY188382A (show.php)
NZ (1) NZ728684A (show.php)
PE (1) PE20170438A1 (show.php)
PH (1) PH12017500453B1 (show.php)
PL (1) PL3191487T3 (show.php)
PT (1) PT3191487T (show.php)
RS (1) RS59444B1 (show.php)
SA (1) SA517381064B1 (show.php)
SG (1) SG11201701633SA (show.php)
SI (1) SI3191487T1 (show.php)
TW (1) TWI687424B (show.php)
UA (1) UA118610C2 (show.php)
WO (1) WO2016038007A1 (show.php)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018227B2 (en) 2010-03-19 2015-04-28 Indiana State University Nicotinic acetylcholine receptor agonists
NO2699580T3 (show.php) 2014-01-24 2018-02-24
JP6529575B2 (ja) * 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
JP2017526716A (ja) 2014-09-12 2017-09-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃのスピロ環状阻害剤
MA47106A (fr) 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
WO2018162312A1 (en) * 2017-03-10 2018-09-13 Basf Se Spirocyclic derivatives
US20190247400A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating granulomatosis with polyangiitis
SI3758708T1 (sl) 2018-03-01 2025-04-30 Astrazeneca Ab Farmacevtski sestavki, ki vsebujejo (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil}-1,4-oksazepan-2-karboksamid
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
CN110256429B (zh) * 2019-06-17 2021-06-22 广东药科大学 一种具有螺环结构的氨基嘧啶类化合物及其制备方法和应用
CN110257504A (zh) * 2019-06-30 2019-09-20 中南大学 一种难治性哮喘检测标记物的筛选方法及其应用
US20230310453A1 (en) 2020-07-20 2023-10-05 Insmed, Inc. Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
CN114106005B (zh) * 2020-08-26 2025-08-01 西藏海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
IL302872A (en) * 2020-11-17 2023-07-01 Vertex Pharma Solid forms of 4-(5-(4-fluorophenyl)-6-tetrahydro-2h-pyran-4-yl)- 1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid
TW202227422A (zh) * 2020-12-04 2022-07-16 大陸商瑞石生物醫藥有限公司 組織蛋白酶ｃ小分子抑制劑及其醫藥用途
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
KR20250022023A (ko) 2022-06-13 2025-02-14 알리벡시스 가부시키가이샤 아자사이클로알킬카보닐 환상 아민 화합물
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
CN120584108A (zh) 2023-01-06 2025-09-02 英斯梅德股份有限公司 新型可逆dpp1抑制剂及其用途
WO2025214464A1 (en) * 2024-04-12 2025-10-16 Insmed Incorporated Crystalline forms of (s) -n- (1-cyano-2- (2-fluoro-4- (1' - (oxetan-3-yl) -3h-spiro [isobenzofuran-1, 4' -piperidin] -6-yl) phenyl) ethyl) -2-azabicyclo [2.2.2] octane-1-carboxamide

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125727A (en) 1976-10-18 1978-11-14 American Cyanamid Company Method of preparing imidazoisoindolediones
GB8922355D0 (en) 1989-10-04 1989-11-22 British Telecomm Sealing gland
GEP20012487B (en) 1998-09-16 2001-07-25 Merab Lomia Use of Chemical Agent 5-carbarnoyl-5H-Dibenz (b,f) azepin, its Derivatives and Analogues by New Purpose
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US7012075B2 (en) 2001-03-02 2006-03-14 Merck & Co., Inc. Cathepsin cysteine protease inhibitors
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
EP1638925A1 (en) 2003-06-18 2006-03-29 Prozymex A/S Protease inhibitors
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
WO2006096807A1 (en) 2005-03-08 2006-09-14 Janssen Pharmaceutica N.V. Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists
HRP20120852T1 (hr) * 2006-06-01 2012-11-30 Sanofi Spirocikliäśki nitrili kao inhibitori proteaze
JPWO2008038692A1 (ja) 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
WO2009047829A1 (ja) 2007-10-12 2009-04-16 Fujitsu Limited Ｉｐ電話自動試験システム及び方法
AU2008334444B2 (en) 2007-12-12 2011-12-15 Astrazeneca Ab Peptidyl nitriles and use thereof as dipeptidyl peptidase I inhibitors
CN102574830A (zh) 2009-05-07 2012-07-11 阿斯利康(瑞典)有限公司 取代的1-氰基乙基杂环基甲酰胺化合物750
WO2010142985A1 (en) 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) * 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
HK1201819A1 (en) 2012-04-27 2015-09-11 Glaxo Group Limited Novel compounds
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
PE20150400A1 (es) 2012-05-22 2015-03-27 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
CN105102456B (zh) 2012-09-28 2017-11-14 癌症研究技术有限公司 非典型蛋白激酶c的氮杂喹唑啉抑制剂
JP2015533134A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 錠剤の機械的安定性に適切な少なくとも１種の水和物形成活性物質及び／又はアジュバントを含有する機械的に安定な錠剤、特にアルギニン含有錠剤の製造における選択的に水分調整された打錠材料の使用
CA2887562C (en) 2012-10-15 2021-01-12 Epizyme, Inc. Substituted benzene compounds
CN105209453B (zh) 2012-10-16 2017-06-20 詹森药业有限公司 ROR‑γ‑T的亚甲基连接的喹啉基调节剂
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
SG11201504754QA (en) 2012-12-21 2015-07-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
SG11201504946VA (en) 2012-12-21 2015-07-30 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2014141104A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
SG10201707545XA (en) 2013-03-14 2017-10-30 Newlink Genetics Corp Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
WO2014140075A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
EP2970252B1 (en) * 2013-03-14 2020-06-03 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
AU2015252343B2 (en) * 2014-04-29 2017-06-08 Shl Medical Ag Device for adjusting needle insertion depth
JP2017521308A (ja) 2014-07-03 2017-08-03 ブリヂストン アメリカズ タイヤ オペレーションズ、 エルエルシー リムガード上のサイドウォールの装飾
TW201625591A (zh) 2014-09-12 2016-07-16 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
JP2017526716A (ja) * 2014-09-12 2017-09-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃのスピロ環状阻害剤
HUE041694T2 (hu) 2014-09-12 2019-05-28 Glaxosmithkline Ip No 2 Ltd Tetrahidrokvinolin származékok mint bromodomén inhibitorok
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa

Also Published As

Publication number Publication date
CN107074870A (zh) 2017-08-18
SG11201701633SA (en) 2017-03-30
EA201790576A1 (ru) 2017-08-31
JP2018044011A (ja) 2018-03-22
CO2017002268A2 (es) 2017-06-20
PL3191487T3 (pl) 2020-03-31
CA2960916A1 (en) 2016-03-17
MX367316B (es) 2019-08-15
SI3191487T1 (sl) 2019-12-31
ES2749009T3 (es) 2020-03-18
IL250262B (en) 2020-03-31
BR112017003433A2 (pt) 2017-11-28
SA517381064B1 (ar) 2021-02-07
CN107074870B (zh) 2019-07-12
PE20170438A1 (es) 2017-04-28
BR112017003433B1 (pt) 2023-11-14
WO2016038007A1 (en) 2016-03-17
HUE047208T2 (hu) 2020-04-28
LT3191487T (lt) 2019-10-10
KR20170054489A (ko) 2017-05-17
PH12017500453A1 (en) 2017-07-31
DK3191487T3 (da) 2019-10-28
MX2017003156A (es) 2017-05-23
EP3191487B1 (en) 2019-08-07
EA031376B1 (ru) 2018-12-28
JP6360961B2 (ja) 2018-07-18
CL2017000432A1 (es) 2017-10-20
US20170073352A1 (en) 2017-03-16
CN108047240A (zh) 2018-05-18
US9540373B2 (en) 2017-01-10
HK1255362A1 (zh) 2019-08-16
CY1123033T1 (el) 2021-10-29
AU2015314355A1 (en) 2017-02-16
PH12017500453B1 (en) 2021-08-06
HRP20191756T1 (hr) 2019-12-27
CN108047240B (zh) 2020-08-04
AP2017009733A0 (en) 2017-02-28
RS59444B1 (sr) 2019-11-29
NZ728684A (en) 2022-09-30
PT3191487T (pt) 2019-11-18
MX2019009695A (es) 2019-10-07
IL250262A0 (en) 2017-03-30
JP2017526716A (ja) 2017-09-14
MX378099B (es) 2025-03-10
UA118610C2 (uk) 2019-02-11
US20160075704A1 (en) 2016-03-17
USRE47636E1 (en) 2019-10-08
TWI687424B (zh) 2020-03-11
TW201625647A (zh) 2016-07-16
EP3191487A1 (en) 2017-07-19
AU2015314355B2 (en) 2019-06-20
KR102510588B1 (ko) 2023-03-17
MY188382A (en) 2021-12-07
EP3511331A1 (en) 2019-07-17
US9879026B2 (en) 2018-01-30

Similar Documents

Publication Publication Date Title
CA2960916C (en) Spirocyclic inhibitors of cathepsin c
JP6689805B2 (ja) カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
EP3174879B1 (en) Substituted oxetanes and their use as inhibitors of cathepsin c
CA2848929A1 (en) Substituted n- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin c
US9073869B2 (en) Method of using substituted 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
EP2970228B1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c
WO2014140081A1 (en) Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
HK1234043B (en) Spirocyclic inhibitors of cathepsin c
HK1234043A1 (en) Spirocyclic inhibitors of cathepsin c

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908